Pacira Counters Activist Investor, Highlights Strategic Progress and Shareholder Returns
summarizeSummary
Pacira BioSciences issued a statement responding to DOMA Perpetual Capital Management's nomination of three director candidates for its board. The company reaffirmed its "5x30 strategy" for value creation, detailing achievements such as treating 2.5 million patients in 2025, 6.2% EXPAREL volume growth, strengthening its intellectual property with 21 patents, achieving record gross margins, advancing two Phase 2 clinical programs, and executing $150 million in share repurchases in 2025. This statement directly follows earlier news today regarding DOMA Perpetual's call for CEO replacement and director nominations, marking the official start of a potential proxy battle. Investors will closely monitor further developments from both parties and the upcoming 2026 Annual Meeting, as the outcome could significantly impact the company's leadership and strategic direction.
At the time of this announcement, PCRX was trading at $22.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $924.4M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.